

# Catalytic antioxidants: a radical approach to new therapeutics

Brian J. Day

In humans, several pathologies involve the overproduction of reactive oxygen species. Metal-containing catalytic antioxidants have emerged as a novel class of potential therapeutic agents that scavenge a wide range of reactive oxygen species. There are three structural classes of manganese-containing catalytic antioxidants that have efficacy in several oxidative stress models of human disease. The classes are divided based on their *in vitro* selectivity towards the scavenging of superoxide. The selective catalytic antioxidants include the macrocyclics, whereas the non-selective catalytic antioxidants include the salens and porphyrins. Cardiovascular, neurodegenerative and inflammatory lung disorders are all potentially important targets for catalytic antioxidant therapy.

Brian J. Day  
National Jewish Medical &  
Research Center  
K715, 1400 Jackson Street  
Denver, CO 80206, USA  
e-mail: [dayb@njc.org](mailto:dayb@njc.org)


▼ Reactive oxygen species (ROS), such as the superoxide radical anion ( $O_2^{\cdot-}$ ) and hydrogen peroxide ( $H_2O_2$ ), are formed in biological systems by the partial reduction of molecular oxygen (Figure 1).  $O_2^{\cdot-}$  is produced from the one-electron reduction of molecular oxygen. Reduction of  $O_2^{\cdot-}$  with a second electron generates  $H_2O_2$ , which can also be formed from a two-electron reduction of molecular oxygen. Formation of the hydroxyl radical ( $HO\cdot$ ), another ROS, is thought to occur through the one-electron reduction of  $H_2O_2$ , a reaction that is facilitated by transition metals that are in a reduced valence state (e.g. reduced copper or iron). Four electrons and two protons are required to reduce molecular oxygen to water ( $H_2O$ ). Additionally, there are a large number of other reactive species that are formed from the reaction of ROS with biological molecules [e.g. polyunsaturated lipids, thiols and nitric oxide (NO)].

$O_2^{\cdot-}$  is generated from the uncoupling of the mitochondrial electron transport chain during oxidative phosphorylation and also by the catalytic action of a variety of intracellular and extracellular oxidases. The production of  $O_2^{\cdot-}$ , which occurs during host defense

responses, is either beneficial or detrimental depending upon the site of formation, the amount generated and the prevalence of antioxidant defenses.  $O_2^{\cdot-}$  is thought to act as a cell-signaling molecule and to contribute to the killing of foreign bacteria [1]. However, during acute and chronic inflammation, the overproduction of  $O_2^{\cdot-}$  has been shown to contribute to tissue damage and injury [2].

$H_2O_2$  is generated directly from  $O_2^{\cdot-}$  through a rapid dismutation reaction that can occur either enzymatically (rate of  $10^9 M^{-1} s^{-1}$ ) or non-enzymatically (rate of  $10^5 M^{-1} s^{-1}$ ). In addition,  $H_2O_2$  is formed enzymatically as a byproduct of lipid metabolism in peroxisomes.  $H_2O_2$  is stable at biological pH, but can participate in  $HO\cdot$  formation in the presence of reduced transition metals.  $H_2O_2$  readily reacts with the thiol functional group and this type of reaction is proposed to be one of the key mechanisms through which ROS participate in cell signaling. Several phosphatases contain sensitive thiol residues; the oxidation of this functionality results in inactivation of the phosphatase [3]. In addition,  $H_2O_2$  alters cell signaling through the oxidation of thiols in transcription factors, such as reducing factor-1, activator protein-1 and nuclear factor- $\kappa B$  [4].

$O_2^{\cdot-}$  and  $H_2O_2$  participate in the formation of several reactive species that have been directly implicated in tissue damage, for example,  $HO\cdot$ .  $O_2^{\cdot-}$  effects the release of iron from iron-containing proteins, thus increasing the concentration of the transition metal that is available to reduce  $H_2O_2$  to  $HO\cdot$ .  $HO\cdot$  is an extremely reactive species that readily oxidizes all cellular macromolecules, including proteins, sugars, lipids and DNA. In addition,  $O_2^{\cdot-}$  readily reacts with NO to form peroxynitrite ( $ONOO^-$ ), which is unstable at physiological pH and rapidly decomposes to form potent



nitrating and oxidizing species [5]. Cellular damage by oxidative modification of cellular macromolecules ensues when ROS are generated in excess of endogenous defenses. ROS are implicated in several pathological processes including tissue injury [6], inflammatory disorders [7], cardiovascular disease [8], pulmonary disease [9] and neurodegenerative diseases [10].


## Catalytic antioxidants

Superoxide dismutases (SODs) and catalase are metalloproteins that catalyze 'dismutation' reactions, which detoxify ROS. A dismutation reaction is defined as a reaction in which two like-molecules react to produce two different products (i.e.  $A + A \rightarrow B + C$ ). SODs catalyze the formation of oxygen and  $H_2O_2$  from two  $O_2^{\bullet-}$ , whereas catalase metalloproteins catalyze the reaction of two  $H_2O_2$  to produce oxygen and water. Because these efficient reactions do not require additional reducing equivalents, no energy is taken from the cell to drive these transformations. The overall goal of cellular antioxidant defenses is to reduce ROS to water. The overexpression of these metalloproteins in cell culture and in whole animals has provided protection against the deleterious effects of a wide range of oxidative stress paradigms [11,12]. The use of SOD and catalase as therapeutic agents to attenuate ROS-induced injury responses has had mixed success [13,14]. The principal limitations of using these proteins are their large sizes, the consequences of which are low cell permeability, a short circulating half-life, antigenicity and high-manufacturing costs. To overcome many of these limitations, an increasing number of low molecular-weight catalytic antioxidants have been developed.

## Development of catalytic antioxidants

The majority of catalytic antioxidants are designed with redox-active metal centers that catalyze the dismutation reaction of  $O_2^{\bullet-}$  and/or  $H_2O_2$  by a mechanism that is similar to the mode of action of the active-site metals of SOD and catalase. An ideal mimetic is stable and non-toxic. Furthermore, the size and charge of a mimetic can be exploited to target crucial cellular sites of oxidative stress.

For many years, it has been recognized that simple metal chelates react with  $O_2^{\bullet-}$  and  $H_2O_2$ . However, the rates of reaction of chelates with these particular ROS are low and the complexes formed are unstable. The search for more stable and active metal chelates has resulted in the discovery of at least three classes of metal-containing catalytic antioxidants. These include the salen, macrocyclic and metalloporphyrin series (Figure 2). Within this group, the compounds are often divided into selective and non-selective classes based on the specificity of the compounds towards  $O_2^{\bullet-}$  in test-tube reactions (this is why these compounds



are often referred to as SOD mimetics). However, these reactions might not have relevance in more complex biological systems, where it is often difficult to demonstrate this type of selectivity. The potencies of catalytic antioxidants are often compared using their 'test tube'  $O_2^{\cdot-}$  and/or  $H_2O_2$  rate constants, which also might not be relevant in more-complex biological systems. This is particularly pertinent given the recent findings that some of these compounds accept electrons from cellular enzymes [15]. The finding that three structurally different classes of catalytic antioxidants are effective in similar oxidative stress models confirms the basic concept that small, efficient, catalytic antioxidants show promise in the treatment of ROS-mediated injuries.

### Antioxidant properties of selective catalytic antioxidants

#### Macrocyclics

The manganese atom (Mn) at the center of the pentaaza-macrocyclic ligand-based mimetics [M series is currently under development by Metaphore Pharmaceuticals (<http://www.metaphore.com>)] is held by five coordination points and is only available for one-electron transfers [16]. Thus, this class of catalytic antioxidant is unique in that they are specific scavengers for  $O_2^{\cdot-}$  (scavenging of  $H_2O_2$  and  $ONOO^-$  requires transfer of two electrons). During the dismutation reaction with  $O_2^{\cdot-}$ , the Mn(II) at the center of the macrocyclic structure undergoes alternate oxidation and reduction, which results in an interchanging valence state between Mn(II) and Mn(III). This unique feature of macrocyclic antioxidants gives them *in vitro* selectivity towards  $O_2^{\cdot-}$ . However, in biological systems, there are several other endogenous compounds that can also participate in one-electron reactions, including flavins and ubiquinones, and it is unclear whether or not macrocyclic antioxidants interact exclusively with  $O_2^{\cdot-}$ . The macrocyclics are effective in many of the same oxidative paradigms that non-selective catalytic antioxidants have been used in. The different classes of catalytic antioxidants have not been directly compared in experimental models, therefore the conditions under which one class holds an advantage over the other are currently not known.

### Antioxidant properties of non-selective catalytic antioxidants

#### Salens

The structures of compounds in the salen class of catalytic antioxidant [EUK series is currently being developed by Eukarion (<http://www.eukarion.com>)] are generally aromatic, substituted ethylenediamine metal complexes. The Mn(III)-containing salen complexes have been reported to

have two key antioxidant properties – the scavenging of  $O_2^{\cdot-}$  and  $H_2O_2$  [17]. However, these compounds have been shown to react with  $ONOO^-$  [18] and are also thought to react with lipid peroxides. The Mn moiety of the salen compound is coordinated by four axial ligands. One of the unique features of these compounds is that the metal center is coordinated to oxygen and nitrogen atoms, which is in contrast to macrocyclics and porphyrins where the metal is coordinated to nitrogen atoms only. The coordination of Mn by four axial ligands results in the formation of several possible valence states, which are thought to be important in the scavenging of a wide variety of ROS and, thus, contribute to the non-selective nature of this class of antioxidant. Salens comprising Mn(III) function as  $O_2^{\cdot-}$  and  $H_2O_2$  scavengers. However, the mode of action of the salen class of compounds has yet to be elucidated, but it is thought that these molecules act by a mechanism comparable to that reported for the metalloporphyrins. The rates at which Mn(III)-containing salens scavenge  $H_2O_2$  are similar to those reported for metalloporphyrins, but are many orders of magnitude less than those documented for endogenous catalase.

#### Metalloporphyrins

Metalloporphyrins [AEOL series is currently being developed by Aeolus Pharmaceuticals, which is a subsidiary of Incara Pharmaceuticals (<http://www.incara.com>)] are structurally different from endogenous protoporphyrins and are classed as synthetic *meso*-substituted porphyrins. Metalloporphyrins have been shown to possess at least four distinct antioxidant properties, which include scavenging  $O_2^{\cdot-}$ ,  $H_2O_2$ ,  $ONOO^-$  and lipid peroxides. Analogous to the salen class of antioxidants, metalloporphyrins contain a Mn moiety that is coordinated by four axial ligands. These non-selective antioxidants participate in the dismutation reaction of  $O_2^{\cdot-}$  through the alternate reduction and oxidation of the Mn moiety, which results in changes in valence between Mn(III) and Mn(II); this is similar to the reduction-oxidation reaction occurring in native SODs. The catalase activity of metalloporphyrins could be attributed to their extensive conjugated ring system that undergoes reversible one-electron oxidations, which is equivalent to the heme prosthetic groups of endogenous catalases and peroxidases [19]. In general, metalloporphyrins with higher SOD activity have greater catalase activity. It is significant that the catalase activity of most metalloporphyrins is less than 1% of native catalases. However, despite this low catalase activity, Mn-containing porphyrins are still able to protect cells from  $H_2O_2$ -mediated toxicity [20]. The mechanism by which metalloporphyrins scavenge  $ONOO^-$  is thought to involve the formation of an

**Table 1. Catalytic antioxidants that are effective in blocking oxidant stress in *in vitro* models**

| Model system                      | Cell type affected | Catalytic antioxidant(s) | Refs |
|-----------------------------------|--------------------|--------------------------|------|
| Cytotoxicity                      |                    |                          |      |
| Hydrogen peroxide                 | Fibroblast         | AEOL10201                | [79] |
| Oxygen and/or glucose deprivation | Neuronal           | AEOL10201                | [80] |
|                                   |                    | AEOL10113                |      |
|                                   |                    | AEOL10150                | [69] |
|                                   |                    | AEOL10216                | [32] |
| Neutrophil-mediated cytotoxicity  | Lymphocytes        | AEOL10201                | [81] |
| MNDA                              | Neuronal           | M40403                   | [82] |
| Paraquat                          | Epithelial         | AEOL10216                | [32] |
| Gentamicin                        | Cochlear cultures  | M40403                   | [83] |
| SOD2 KO                           | Neuronal           | AEOL10201                | [84] |
|                                   |                    | AEOL10113                |      |
| Apoptosis                         |                    |                          |      |
| T-cell receptor activation        | Lymphocytes        | AEOL10201                | [85] |
| 6-Hydroxydopamine                 | Neuronal           | EUK134                   | [86] |
| Staurosporin                      | Neuronal           | EUK134                   | [86] |
|                                   |                    | EUK189                   |      |
| HIV                               | Astrocytes         | M40401                   | [87] |
| Hyperoxia                         | Epithelial         | EUK134                   | [88] |
| Diseal exhaust particles          | Epithelial         | EUK8                     | [89] |
| Zinc                              | Neuronal           | EUK134                   | [90] |
| Cyclic strain                     | Myocytes           | EUK8                     | [91] |
|                                   |                    | AEOL10110                |      |
| MPP+                              | Neuronal           | AEOL10201                | [92] |
|                                   |                    | EUK134                   | [93] |

Abbreviations: KO, knockout; MNDA, *N*-methyl-D-aspartate; MPP+, 1-methyl-4-phenylpyridinium; SOD, superoxide dismutase.

oxo-Mn(IV) complex that is readily reduced to the Mn(III) oxidation state by a wide variety of endogenous antioxidants (e.g. ascorbate and glutathione), and even by O<sub>2</sub><sup>•-</sup> [21]. The exact mechanism of metalloporphyrin-mediated inhibition of lipid peroxidation is not known, but it is thought to be similar to the mode of action described for metalloporphyrin-scavenging of ONOO<sup>-</sup>.

**Catalytic antioxidants are effective in blocking oxidant stress *in vitro***

*Cytotoxicity*

*In vitro* models of oxidative stress have proved useful in terms of confirming the antioxidant activities of catalytic antioxidants obtained from cell-free systems, and for predicting the utility of these compounds as antioxidants in more complex *in vivo* models of human disease. Given the

large volume of literature on catalytic antioxidants, this review will focus on recent findings (2000 to present); earlier literature has previously been comprehensively reviewed [22–24]. Members of all classes of catalytic antioxidant have been shown to be effective in blocking oxidant stress in a wide variety of *in vitro* cytotoxicity models involving the independent or concomitant generation of O<sub>2</sub><sup>•-</sup>, H<sub>2</sub>O<sub>2</sub> and ONOO<sup>-</sup> species (Table 1). However, there is still some debate as to the mechanism of action of these compounds that affords this defensive effect. Because the reaction of O<sub>2</sub><sup>•-</sup> with different species can lead to the formation of several ROS, it is not surprising that selective and non-selective catalytic antioxidants show similar efficacy in these model systems. At μmolar levels, catalytic antioxidants appear non-toxic and protect a wide variety of different types of cultured cells against the toxicity of ROS.

*Apoptosis*

Apoptosis is a form of cell death that is biochemically and morphologically distinct from necrosis and that subserves physiological and pathological roles in organisms. Although the demonstration that cells undergo apoptosis when oxygen levels are low and the finding that many antioxidants fail to prevent apoptosis argue against a causal role of ROS in

some apoptotic pathways, there is a large body of evidence that supports the involvement of ROS in apoptotic cell death. The release of proapoptotic factors by mitochondria, which are the major source of cellular ROS, lends further support to this argument. Furthermore, demonstrations that the delivery of SOD to neurons is protective [25,26], whereas its paucity is deleterious [27], suggest that O<sub>2</sub><sup>•-</sup> is involved in neuronal apoptosis. A wide variety of apoptosis paradigms can be blocked with selective and non-selective catalytic antioxidants (Table 1). These models range from xenobiotic-induced models to physiologic models, and even to mechanical models. In addition, the cells types vary from immune cells to epithelial cells to neuronal cells. It is not clear from these studies whether the catalytic antioxidants affect a particular point in the intrinsic and/or extrinsic apoptotic pathways. However,

recent studies suggest that ROS might regulate the expression of bcl-2 and that catalytic antioxidants might indirectly block apoptosis by increasing the expression of this antiapoptotic factor [28].

**Catalytic antioxidants are effective in blocking oxidant stress *ex vivo***

Catalytic antioxidants have been shown to be therapeutically effective in several *ex vivo* model systems (Table 2), including models of cardiac hypertrophy [29], vessel dysfunction [30], endotoxin [31], lipid peroxidation [15,32], compression injury [33] and oxidative paradigms in hippocampal slices [34,35]. The majority of these model systems involve the overproduction of ROS by NADPH oxidases and, in some instances, their interaction with NO.

NO is an important modulator of vessel tone and is rapidly inactivated by O<sub>2</sub><sup>•-</sup>. Therefore, inappropriate interplay between these reactive species can disrupt vessel function. Catalytic antioxidants have been shown to block the effects of the angiotensin II-induced elevation of O<sub>2</sub><sup>•-</sup> levels in vessels, which results in hypertension [36]. Vessel dysfunction is also associated with arteriosclerosis and ROS have been implicated in the pathogenesis of this condition. Catalytic antioxidants are effective in attenuating vessel dysfunction in aorta from animal models of arteriosclerosis [30,37]. These data, together with promising studies in whole animals, suggest a potential utility of these agents in a variety of human vascular diseases, including hypertension, pulmonary hypertension, Raynaud's disease and arteriosclerosis.

**Catalytic antioxidants are effective in blocking oxidant stress *in vivo***

The beneficial effects of catalytic antioxidants have been demonstrated in several *in vivo* model systems (Table 3), including models of lung fibrosis [38,39], chronic obstructive lung diseases [40], asthma [41], acute respiratory distress syndrome [42], bronchopulmonary dysplasia [43], pleurisy [44], shock [45–50], myocardial infarction [51,52], liver failure [53,54], ischemia–reperfusion [55,56], colitis [57,58], diabetes [59], transplantation [60], arthritis [61], amyotrophic lateral sclerosis [62,63], migraine [64,65], neurodegenerative diseases [66], stroke [67–70], spinal cord injury [71,72], pain [73] and dementia [74]. The efficacy of

| Table 2. Catalytic antioxidants that are effective in blocking antioxidant stress in <i>ex vivo</i> models |                       |                          |      |
|------------------------------------------------------------------------------------------------------------|-----------------------|--------------------------|------|
| Model system                                                                                               | Organ and/or tissue   | Catalytic antioxidant(s) | Refs |
| Cardiac hypertrophy                                                                                        | Isolated heart        | AEOL10110                | [29] |
| Endotoxin                                                                                                  | Peritoneal macrophage | AEOL10201                | [31] |
| Vessel dysfunction                                                                                         | ApoE KO               | AEOL10201                | [30] |
|                                                                                                            | Aorta                 | M40403                   | [37] |
| Angiotensin II-induced vasoconstriction                                                                    | Aorta                 | EUK8                     | [36] |
| Compression injury                                                                                         | Cartilage             | AEOL10110                | [33] |
| Lipid peroxidation                                                                                         | Brain homogenate      | AEOL10216                | [32] |
|                                                                                                            |                       | AEOL10123                | [15] |
|                                                                                                            |                       | AEOL10150                |      |
|                                                                                                            | LDL                   | AEOL10158                |      |
|                                                                                                            |                       | AEOL10113                | [94] |
|                                                                                                            |                       | AEOL10201                |      |
| Iron                                                                                                       | Hippocampal slices    | AEOL10170                |      |
| Kainate                                                                                                    | Hippocampal slices    | EUK134                   | [34] |
|                                                                                                            |                       | EUK134                   | [35] |

Abbreviations: ApoE, apolipoprotein E; KO, knockout; LDL, low-density lipoprotein

catalytic antioxidants demonstrated in an incredible diversity of model systems highlights the extensive involvement of ROS in common animal models of human disease.

*Lung models*

The lung functions at a higher oxygen tension than most other organs and, therefore, has a unique relationship with ROS. There is mounting evidence that indicates ROS have a key role in several lung diseases [9]. A common modality among lung diseases is an inappropriate inflammatory response. Catalytic antioxidants decrease airway hyper-reactivity and inflammation in an antigen-induced mouse model of asthma [41]. Chronic obstructive pulmonary disease (COPD), which includes emphysema and bronchitis, is often associated with cigarette smoke; the combustion products of tobacco smoke have high levels of ROS. Catalytic antioxidants suppressed inflammation and protected the rat lung epithelium from cigarette smoke-induced precancerous lesions [40]. Interstitial lung disease is also associated with an increased oxidant burden and many animal models of pulmonary fibrosis use agents, such as bleomycin or ionizing radiation, that overproduce ROS [9]. Catalytic antioxidants attenuate lung fibrosis that has been induced by either bleomycin [38] or ionizing radiation [39]. Bronchopulmonary dysplasia occurs in premature infants where the lung is not fully developed and requires additional supplemental oxygen for adequate gas

**Table 3. Catalytic antioxidants that are effective in blocking antioxidant stress in *in vivo* models**

| Model system                         | Species used for model system | Catalytic antioxidant(s) | Refs         | Model system                                  | Species used for model system | Catalytic antioxidant(s) | Refs |
|--------------------------------------|-------------------------------|--------------------------|--------------|-----------------------------------------------|-------------------------------|--------------------------|------|
| <b>Lung</b>                          |                               |                          |              | ALS                                           | SOD1 Tg mice                  | EUK8<br>EUK134           | [63] |
| Bleomycin fibrosis                   | Mice                          | AEOL10201                | [38]         | Spinal cord injury                            | Rats                          | AEOL10201                | [71] |
| Radiation fibrosis                   | Rats                          | AEOL10113                | [39]         | Spongiform encephalopathy                     | SOD2 KO mice                  | EUK8<br>EUK134           | [77] |
| Cigarette smoke injury               | Rats                          | AEOL10150                | [40]         | Ischemia–reperfusion                          | Rats                          | AEOL10113                | [68] |
| Antigen-induced asthma               | Mice                          | AEOL10113                | [41]         |                                               | Mice                          | AEOL10150                | [69] |
| Hemorrhage-induced injury            | SOD3 KO mice                  | AEOL10150                | [42]         |                                               | Gerbils                       | M40401                   | [70] |
| Bronchopulmonary dysplasia           | Baboon                        | AEOL10113                | [43]         | Phencyclidine injury                          | Rats                          | M40401                   | [97] |
| Carrageenan-induced inflammation     | Rats                          | M40403                   | [44]         | Hyperalgesia                                  | Rats                          | M40403                   | [73] |
| <b>Cardiovascular</b>                |                               |                          |              | Age-induced cognitive impairment              | Mice                          | EUK189<br>EUK207         | [74] |
| Splanchnic artery occlusion          | Rats                          | AEOL10217                | [50]         | Meningitis-induced hearing loss               | Rats                          | AEOL10201                | [98] |
| Heart ischemia–reperfusion           | Rats                          | M40403<br>EUK8           | [51]<br>[52] | <b>Liver</b>                                  |                               |                          |      |
| Hemorrhagic shock                    | Rats                          | EUK8<br>EUK134           | [45]         | Acetaminophen injury                          | Mice                          | AEOL10201                | [53] |
| Nitrate tolerance                    | Rats                          | AEOL10201                | [95]         | Fas-induced injury                            | Mice                          | AEOL10201                | [54] |
| Interleukin-2-induced hypotension    | Mice                          | M40403                   | [46]         | Ischemia–reperfusion                          | Rat                           | AEOL10150                | [55] |
| Endotoxin-induced shock              | Rats                          | M40401<br>EUK8           | [47]<br>[48] | <b>Gastrointestinal</b>                       |                               |                          |      |
| Hypoxic pulmonary vasoconstriction   | Mice                          | EUK8                     | [96]         | Acetic acid-induced colitis                   | Rats                          | AEOL11201                | [57] |
| <b>Central nervous system</b>        |                               |                          |              | Trinitrobenzene sulfonic acid-induced colitis | Rats                          | M40403                   | [58] |
| Kainite injury                       | SOD2 KO mice                  | AEOL10201                | [66]         | <b>Renal</b>                                  |                               |                          |      |
| Cerebral vasoconstriction            | Amyloid Tg mice               | AEOL10201                | [65]         | Gentamicin injury                             | Rats                          | M40403                   | [99] |
|                                      | Rats                          | AEOL10201                | [67]         | Endotoxin                                     | Mice                          | AEOL10113                | [49] |
| A- $\beta$ cerebral vasoconstriction | Mice                          | AEOL10201                | [64]         | Ischemic–reperfusion                          | Rats                          | EUK134                   | [56] |
|                                      |                               |                          |              | <b>Endocrine</b>                              |                               |                          |      |
|                                      |                               |                          |              | Diabetes                                      | NOD mice                      | AEOL10113                | [59] |
|                                      |                               |                          |              | <b>Joint</b>                                  |                               |                          |      |
|                                      |                               |                          |              | Collagen-induced arthritis                    | Rats                          | M40403                   | [61] |

Abbreviations: A- $\beta$ , amyloid- $\beta$ ; ALS, amyotrophic lateral sclerosis; NOD, non-obese diabetic; SOD, superoxide dismutase; Tg, transgenic.

exchange. Catalytic antioxidants suppress lung inflammation and improve lung function in a hyperoxic model of bronchopulmonary dysplasia in preterm baboons [43]. Acute respiratory distress syndrome (ARDS) is associated with sepsis and shock (conditions that are also linked to excessive ROS production) and catalytic antioxidants have shown effectiveness in several of these types of animal models [42,45,48,75].

Many of the current therapies for the treatment of lung disease are directed towards alleviating the symptoms of these diseases, but there is a medical need for therapeutics that slow or prevent the progression of lung disease. Research implicating ROS in lung disease supports the development of catalytic antioxidants for the treatment of asthma, COPD, ARDS, bronchopulmonary dysplasia and interstitial lung disease.

### *Cardiovascular models*

A common complication of bacterial sepsis is the phenomenon referred to as 'endotoxic shock', which results in oxidative tissue damage that is partially attributed to the formation of ONOO<sup>-</sup>. A serious consequence of endotoxic shock is the loss of responsiveness to vasoconstrictive agents. Selective and non-selective catalytic antioxidants are effective in endotoxin models, which is probably related to their ability to scavenge O<sub>2</sub><sup>-•</sup> and/or ONOO<sup>-</sup> [45–48,50].

Another common cause of tissue injury, which is often associated with cardiac damage in myocardial infarction, arrhythmias, angina, myocardial stunning and transplantation, occurs during ischemia and subsequent reoxygenation or reperfusion. The role of excessive ROS production during ischemia–reperfusion and the protective effects of endogenous antioxidants have been well documented [76]. Selective and non-selective catalytic antioxidants are effective in a rat model of heart ischemia–reperfusion [51,52]. In addition to heart models of ischemia–reperfusion, several other organs have been shown to benefit from catalytic antioxidant treatment, including the liver [55] and the kidney [56].

Currently, there are few treatment options for either sepsis or tissue injury associated with ischemia–reperfusion. The overproduction of ROS is a key mechanism in the development of ischemia–reperfusion and the abundance of literature reporting a protective effect of antioxidants in this condition makes this a particularly attractive area for the development of catalytic antioxidant therapeutics.

### *Central nervous system models*

As a result of the high levels of oxygen required by the brain, this organ is particularly sensitive to ROS-mediated damage. Other factors that exacerbate this sensitivity are the presence of autooxidizable neurotransmitters and a high concentration of polyunsaturated fatty acids in neuronal membranes. Furthermore, the brain has only low levels of endogenous antioxidants to protect itself from oxidative damage. Collectively, these factors make catalytic antioxidants good candidates for several acute and chronic neuronal disorders that involve the overproduction of ROS, for example, Parkinson's disease (PD), Huntington's disease (HD), Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), status epilepticus, stroke and trauma. Excitotoxicity (neuronal death resulting from excessive stimulation of glutamate receptors), leads to increased ROS production, which is a key pathological process in neurological disorders. Mice that lack SOD2 develop a fatal neurodegenerative phenotype that can be rescued by catalytic antioxidants [77]. Furthermore, mice that overexpress

SOD2 are protected against excitotoxic injury that is induced by kainate, whereas heterozygous SOD2 knockout mice show exacerbated damage [66]. Neurons cultured from SOD2 knockout mice spontaneously die in normoxic culture conditions, but can be rescued by catalytic antioxidants [78].

Stroke is a neurodegenerative condition that often involves tissue injury that occurs during ischemia–reperfusion. These events are associated with the overproduction of ROS and can be enhanced or attenuated by modulation of endogenous SOD levels. Catalytic antioxidants are effective in attenuating cerebral vasoconstriction, which is commonly associated with hemorrhagic stroke and migraines [64,65,67]. Catalytic antioxidants are also effective in rodent vessel occlusion models of stroke [68–70].

Pain management still poses clinical challenges, particularly with the large potential of addiction to opiates. NO could play a role in inflammatory pain perception. Considering the interplay between NO and O<sub>2</sub><sup>-•</sup>, it could be anticipated that ROS and antioxidants modulate pain perception. A selective catalytic antioxidant (M40403) has recently been shown to block inflammation and hyperalgesia in a rat carrageenan model [73]. These data suggest that catalytic antioxidants could be developed as non-narcotic analgesic agents. Interestingly, this is also the first indication that catalytic antioxidants are being clinically tested.

These studies indicate that neuronal disorders such as ALS, trauma, pain, stroke and associated cerebral vascular disease might be amenable to catalytic antioxidant treatment. These conditions affect a large portion of the human population, but, unfortunately, there are few therapeutic options available for the treatment of many of these diseases.

### **Implications for the use of catalytic antioxidants in the therapy of human disease**

The postulated role of ROS as final common mediators of tissue damage in diseases of diverse etiologies emphasizes the wide range of therapeutic applications of catalytic antioxidants. Pathologies that are most likely to benefit from catalytic antioxidant therapy include conditions in which a clear role for ROS has been established. Inflammation, which is a key etiological factor that accompanies diseases involving multiple organs, comprises a major therapeutic area for antioxidant therapy. In the immune system, O<sub>2</sub><sup>-•</sup> production can be triggered by host defense mechanisms such as phagocytosis, inflammatory cytokines, chemokines and immune complex formation that contribute to autoimmune diseases. Inflammatory lung, intestinal and cardiovascular disorders are all potentially important targets for catalytic antioxidant therapy.

Another major target of catalytic antioxidant therapy are diseases in which cell death occurs with or without ancillary inflammation. ROS modulate intrinsic and extrinsic apoptosis pathways and, therefore, neurodegenerative diseases that are associated with excess apoptosis are potential therapeutic targets and include PD, HD, AD, ALS, epilepsy, stroke and trauma. The detection of cell death processes occurring with and without ancillary inflammation in several of these neurodegenerative diseases provokes the speculation that the use of catalytic antioxidants that prevent some forms of apoptosis and necrosis could be particularly beneficial in the treatment of these conditions. Finally, in addition to being a key component of host defense, ROS have physiological roles in cell signaling and, consequently, the control of gene expression, which are processes that could be disrupted by antioxidant therapies. However, the carefully controlled titration of the amount of catalytic antioxidants administered to treat these disease conditions could potentially facilitate the scavenging of excess ROS, and thus restore redox balance and health to the tissue.

## Acknowledgements

I thank Manisha Patel for her helpful suggestions and comments on the manuscript.

## References

- Simon, A.R. *et al.* (1998) Activation of the JAK-STAT pathway by reactive oxygen species. *Am. J. Physiol.* 275, C1640-C1652
- Salvemini, D. *et al.* (2003) Roles of nitric oxide and superoxide in inflammation. *Methods Mol. Biol.* 225, 291-303
- Rhee, S.G. *et al.* (2000) Hydrogen peroxide: a key messenger that modulates protein phosphorylation through cysteine oxidation. *Sci. STKE* 53, PE1
- Finkel, T. (2000) Redox-dependent signal transduction. *FEBS Lett.* 476, 52-54
- Beckman, J.S. *et al.* (1990) Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. *Proc. Natl. Acad. Sci. U. S. A.* 87, 1620-1624
- Freeman, B.A. and Crapo, J.D. (1982) Biology of disease: free radicals and tissue injury. *Lab. Invest.* 47, 412-426
- McCord, J.M. and Fridovich, I. (1978) The biology and pathology of oxygen radicals. *Ann. Intern. Med.* 89, 122-127
- Maxwell, S.R. and Lip, G.Y. (1997) Free radicals and antioxidants in cardiovascular disease. *Br. J. Clin. Pharmacol.* 44, 307-317
- Kinnula, V.L. and Crapo, J.D. (2003) Superoxide dismutases in the lung and human lung diseases. *Am. J. Respir. Crit. Care Med.* 167, 1600-1619
- Halliwell, B. (1992) Reactive oxygen species and the central nervous system. *J. Neurochem.* 59, 1609-1623
- Ho, Y.S. *et al.* (1998) Transgenic models for the study of lung antioxidant defense: enhanced manganese-containing superoxide dismutase activity gives partial protection to B6C3 hybrid mice exposed to hyperoxia. *Am. J. Respir. Cell Mol. Biol.* 18, 538-547
- Li, G. *et al.* (1997) Catalase-overexpressing transgenic mouse heart is resistant to ischemia-reperfusion injury. *Am. J. Physiol.* 273, H1090-H1095
- Simonson, S.G. *et al.* (1997) Aerosolized manganese SOD decreases hyperoxic pulmonary injury in primates. I. Physiology and biochemistry. *J. Appl. Physiol.* 83, 550-558
- Shaffer, S.G. *et al.* (1987) Administration of bovine superoxide dismutase fails to prevent chronic pulmonary sequelae of neonatal oxygen exposure in the rat. *J. Pediatr.* 110, 942-946
- Kachadourian, R. *et al.* (2004) Flavin-dependent antioxidant properties of a new series of *meso-N,N'*-dialkyl-imidazolium substituted manganese (III) porphyrins. *Biochem. Pharmacol.* 67, 77-85
- Riley, D.P. *et al.* (1997) Toward the rational design of superoxide dismutase mimics: mechanistic studies for the elucidation of substituent effects on the catalytic activity of macrocyclic manganese (II) complexes. *J. Am. Chem. Soc.* 119, 6522-6528
- Doctrow, S.R. *et al.* (1997) Salen-manganese complexes: combined superoxide dismutase/catalase mimics with broad pharmacological efficacy. *Adv. Pharmacol.* 38, 247-269
- Sharpe, M.A. *et al.* (2002) Oxidation of nitric oxide by oxomanganese-salen complexes: a new mechanism for cellular protection by superoxide dismutase/catalase mimetics. *Biochem. J.* 366, 97-107
- Dolphin, D. *et al.* (1971) Compounds I of catalase and horse radish peroxidase: pi-cation radicals. *Proc. Natl. Acad. Sci. U. S. A.* 68, 614-618
- Day, B.J. *et al.* (1997) Manganic porphyrins possess catalase activity and protect endothelial cells against hydrogen peroxide-mediated injury. *Arch. Biochem. Biophys.* 347, 256-262
- Lee, J. and Groves, J.T. (1998) Manganese porphyrins as redox-coupled peroxynitrite reductases. *J. Am. Chem. Soc.* 120, 6053-6061
- Patel, M. and Day, B.J. (1999) Metalloporphyrin class of therapeutic catalytic antioxidants. *Trends Pharmacol. Sci.* 20, 359-364
- Doctrow, S.R. *et al.* (2002) Salen-manganese complexes as catalytic scavengers of hydrogen peroxide and cytoprotective agents: structure-activity relationship studies. *J. Med. Chem.* 45, 4549-4558
- Salvemini, D. *et al.* (2002) SOD mimetics are coming of age. *Nat. Rev. Drug Discov.* 1, 367-374
- Greenlund, L.J. *et al.* (1995) Superoxide dismutase delays neuronal apoptosis: a role for reactive oxygen species in programmed neuronal death. *Neuron* 14, 303-315
- Jordan, J. *et al.* (1995) Expression of human copper/zinc-superoxide dismutase inhibits the death of rat sympathetic neurons caused by withdrawal of nerve growth factor. *Mol. Pharmacol.* 47, 1095-1100
- Troy, C.M. and Shelanski, M.L. (1994) Down-regulation of copper/zinc superoxide dismutase causes apoptotic death in PC12 neuronal cells. *Proc. Natl. Acad. Sci. U. S. A.* 91, 6384-6387
- Hildeman, D.A. *et al.* (2003) Control of Bcl-2 expression by reactive oxygen species. *Proc. Natl. Acad. Sci. U. S. A.* 100, 15035-15040
- MacCarthy, P.A. *et al.* (2001) Impaired endothelial regulation of ventricular relaxation in cardiac hypertrophy: role of reactive oxygen species and NADPH oxidase. *Circulation* 104, 2967-2974
- d'Uscio, L.V. *et al.* (2001) Hypercholesterolemia impairs endothelium-dependent relaxations in common carotid arteries of apolipoprotein e-deficient mice. *Stroke* 32, 2658-2664
- Pfeiffer, S. *et al.* (2001) Protein tyrosine nitration in mouse peritoneal macrophages activated *in vitro* and *in vivo*: evidence against an essential role of peroxynitrite. *FASEB J.* 15, 2355-2364
- Kachadourian, R. *et al.* (2003) Synthesis and *in vitro* antioxidant properties of manganese (III) beta-octabromo-*meso*-tetrakis(4-carboxyphenyl)porphyrin. *J. Inorg. Biochem.* 95, 240-248
- Kurz, B. *et al.* (2004) Influence of tissue maturation and antioxidants on the apoptotic response of articular cartilage after injurious compression. *Arthritis Rheum.* 50, 123-130
- Liu, R. *et al.* (2003) Iron toxicity in organotypic cultures of hippocampal slices: role of reactive oxygen species. *J. Neurochem.* 85, 492-502
- Liu, W. *et al.* (2001) Role of polyamine metabolism in kainic acid excitotoxicity in organotypic hippocampal slice cultures. *J. Neurochem.* 79, 976-984
- de Groot, A.A. *et al.* (2004) Involvement of reactive oxygen species in angiotensin II-induced vasoconstriction. *J. Cardiovasc. Pharmacol.* 43, 154-159
- Jiang, F. *et al.* (2003) Superoxide dismutase mimetic M40403 improves

- endothelial function in apolipoprotein(E)-deficient mice. *Br. J. Pharmacol.* 139, 1127–1134
- 38 Oury, T.D. *et al.* (2001) Attenuation of bleomycin-induced pulmonary fibrosis by a catalytic antioxidant metalloporphyrin. *Am. J. Respir. Cell Mol. Biol.* 25, 164–169
  - 39 Vujaskovic, Z. *et al.* (2002) A small molecular weight catalytic metalloporphyrin antioxidant with superoxide dismutase (SOD) mimetic properties protects lungs from radiation-induced injury. *Free Radic. Biol. Med.* 33, 857–863
  - 40 Smith, K.R. *et al.* (2002) Inhibition of tobacco smoke-induced lung inflammation by a catalytic antioxidant. *Free Radic. Biol. Med.* 33, 1106–1114
  - 41 Chang, L.Y. and Crapo, J.D. (2002) Inhibition of airway inflammation and hyperreactivity by an antioxidant mimetic. *Free Radic. Biol. Med.* 33, 379–386
  - 42 Bowler, R.P. *et al.* (2003) Evidence for extracellular superoxide dismutase as a mediator of hemorrhage-induced lung injury. *Am. J. Physiol. Lung Cell Mol. Physiol.* 284, L680–L687
  - 43 Chang, L.Y. *et al.* (2003) A catalytic antioxidant attenuates alveolar structural remodeling in bronchopulmonary dysplasia. *Am. J. Respir. Crit. Care Med.* 167, 57–64
  - 44 Salvemini, D. *et al.* (2001) Pharmacological manipulation of the inflammatory cascade by the superoxide dismutase mimetic, M40403. *Br. J. Pharmacol.* 132, 815–827
  - 45 Izumi, M. *et al.* (2002) Superoxide dismutase mimetics with catalase activity reduce the organ injury in hemorrhagic shock. *Shock* 18, 230–235
  - 46 Samlowski, W.E. *et al.* (2003) A nonpeptidyl mimic of superoxide dismutase, M40403, inhibits dose-limiting hypotension associated with interleukin-2 and increases its antitumor effects. *Nat. Med.* 9, 750–755
  - 47 Macarthur, H. *et al.* (2003) Modulation of serum cytokine levels by a novel superoxide dismutase mimetic, M40401, in an *Escherichia coli* model of septic shock: correlation with preserved circulating catecholamines. *Crit. Care Med.* 31, 237–245
  - 48 McDonald, M.C. *et al.* (2003) A superoxide dismutase mimetic with catalase activity (EUK-8) reduces the organ injury in endotoxic shock. *Eur. J. Pharmacol.* 466, 181–189
  - 49 Wang, W. *et al.* (2003) Interaction among nitric oxide, reactive oxygen species, and antioxidants during endotoxemia-related acute renal failure. *Am. J. Physiol. Renal Physiol.* 284, F532–F537
  - 50 Cuzzocrea, S. *et al.* (2000) Beneficial effects of peroxynitrite decomposition catalyst in a rat model of splanchnic artery occlusion and reperfusion. *FASEB J.* 14, 1061–1072
  - 51 Masini, E. *et al.* (2002) Protective effects of M40403, a selective superoxide dismutase mimetic, in myocardial ischaemia and reperfusion injury *in vivo*. *Br. J. Pharmacol.* 136, 905–917
  - 52 Xu, Y. *et al.* Cardioprotection by chronic estrogen or superoxide dismutase mimetic treatment in the aged female rat. *Am. J. Physiol.* (in press)
  - 53 Ferret, P.J. *et al.* (2001) Detoxification of reactive oxygen species by a nonpeptidyl mimic of superoxide dismutase cures acetaminophen-induced acute liver failure in the mouse. *Hepatology* 33, 1173–1180
  - 54 Malassagne, B. *et al.* (2001) The superoxide dismutase mimetic MnTBAP prevents Fas-induced acute liver failure in the mouse. *Gastroenterology* 121, 1451–1459
  - 55 Hines, I.N. *et al.* (2003) Regulation of postischemic liver injury following different durations of ischemia. *Am. J. Physiol. Gastrointest. Liver Physiol.* 284, G536–G545
  - 56 Chatterjee, P.K. *et al.* (2004) EUK-134 reduces renal dysfunction and injury caused by oxidative and nitrosative stress of the kidney. *Am. J. Nephrol.* 24, 165–177
  - 57 Choudhary, S. *et al.* (2001) Novel antioxidants zolimid and AEOL11201 ameliorate colitis in rats. *Dig. Dis. Sci.* 46, 2222–2230
  - 58 Cuzzocrea, S. *et al.* (2001) Protective effects of M40403, a superoxide dismutase mimetic, in a rodent model of colitis. *Eur. J. Pharmacol.* 432, 79–89
  - 59 Piganelli, J.D. *et al.* (2002) A metalloporphyrin-based superoxide dismutase mimic inhibits adoptive transfer of autoimmune diabetes by a diabetogenic T-cell clone. *Diabetes* 51, 347–355
  - 60 Bottino, R. *et al.* (2002) Preservation of human islet cell functional mass by anti-oxidative action of a novel SOD mimic compound. *Diabetes* 51, 2561–2567
  - 61 Salvemini, D. *et al.* (2001) Amelioration of joint disease in a rat model of collagen-induced arthritis by M40403, a superoxide dismutase mimetic. *Arthritis Rheum.* 44, 2909–2921
  - 62 Wu, A.S. *et al.* (2003) Iron porphyrin treatment extends survival in a transgenic animal model of amyotrophic lateral sclerosis. *J. Neurochem.* 85, 142–150
  - 63 Jung, C. *et al.* (2001) Synthetic superoxide dismutase/catalase mimetics reduce oxidative stress and prolong survival in a mouse amyotrophic lateral sclerosis model. *Neurosci. Lett.* 304, 157–160
  - 64 Niwa, K. *et al.* (2001) A-beta-peptides enhance vasoconstriction in cerebral circulation. *Am. J. Physiol. Heart Circ. Physiol.* 281, H2417–H2424
  - 65 Niwa, K. *et al.* (2000) Exogenous A-beta1-40 reproduces cerebrovascular alterations resulting from amyloid precursor protein overexpression in mice. *J. Cereb. Blood Flow Metab.* 20, 1659–1668
  - 66 Liang, L.P. *et al.* (2000) Mitochondrial superoxide production in kainate-induced hippocampal damage. *Neuroscience* 101, 563–570
  - 67 Aladag, M.A. *et al.* (2003) The attenuation of vasospasm by using a sod mimetic after experimental subarachnoidal haemorrhage in rats. *Acta Neurochir. (Wien)* 145, 673–677
  - 68 Mackensen, G.B. *et al.* (2001) Neuroprotection from delayed postischemic administration of a metalloporphyrin catalytic antioxidant. *J. Neurosci.* 21, 4582–4592
  - 69 Sheng, H. *et al.* (2002) Effects of metalloporphyrin catalytic antioxidants in experimental brain ischemia. *Free Radic. Biol. Med.* 33, 947–961
  - 70 Mollace, V. *et al.* (2003) The protective effect of M40401, a superoxide dismutase mimetic, on post-ischemic brain damage in Mongolian gerbils. *BMC Pharmacol.* 3, 8
  - 71 Leski, M.L. *et al.* (2001) Protein and DNA oxidation in spinal injury: neurofilaments – an oxidation target. *Free Radic. Biol. Med.* 30, 613–624
  - 72 Liu, D. *et al.* (2000) The role of reactive nitrogen species in secondary spinal cord injury: formation of nitric oxide, peroxynitrite, and nitrated protein. *J. Neurochem.* 75, 2144–2154
  - 73 Wang, Z.Q. *et al.* A newly identified role for superoxide in inflammatory pain. *J. Pharmacol. Exp. Ther.* (in press)
  - 74 Liu, R. *et al.* (2003) Reversal of age-related learning deficits and brain oxidative stress in mice with superoxide dismutase/catalase mimetics. *Proc. Natl. Acad. Sci. U. S. A.* 100, 8526–8531
  - 75 Macarthur, H. *et al.* (2000) Inactivation of catecholamines by superoxide gives new insights on the pathogenesis of septic shock. *Proc. Natl. Acad. Sci. U. S. A.* 97, 9753–9758
  - 76 McCord, J.M. (1985) Oxygen-derived free radicals in postischemic tissue injury. *N. Engl. J. Med.* 312, 159–163
  - 77 Melov, S. *et al.* (2001) Lifespan extension and rescue of spongiform encephalopathy in superoxide dismutase 2 nullizygous mice treated with superoxide dismutase-catalase mimetics. *J. Neurosci.* 21, 8348–8353
  - 78 Patel, M. (1998) Inhibition of neuronal apoptosis by a metalloporphyrin superoxide dismutase mimic. *J. Neurochem.* 71, 1068–1074
  - 79 Milano, J. and Day, B.J. (2000) A catalytic antioxidant metalloporphyrin blocks hydrogen peroxide-induced mitochondrial DNA damage. *Nucleic Acids Res.* 28, 968–973
  - 80 Li, Q.Y. *et al.* (2001) Dependence of excitotoxic neurodegeneration on mitochondrial aconitase inactivation. *J. Neurochem.* 78, 746–755
  - 81 Cemerski, S. *et al.* (2002) Reactive oxygen species differentially affect T cell receptor-signaling pathways. *J. Biol. Chem.* 277, 19585–19593
  - 82 McInnis, J. *et al.* (2002) The role of superoxide and nuclear factor-kappaB signaling in N-methyl-D-aspartate-induced necrosis and apoptosis. *J. Pharmacol. Exp. Ther.* 301, 478–487

- 83 McFadden, S.L. *et al.* (2003) M40403, a superoxide dismutase mimetic, protects cochlear hair cells from gentamicin, but not cisplatin toxicity. *Toxicol. Appl. Pharmacol.* 186, 46–54
- 84 Patel, M.N. (2003) Metalloporphyrins improve the survival of Sod2-deficient neurons. *Aging Cell* 2, 219–222
- 85 Kusmartsev, S.A. *et al.* (2000) Gr-1+ myeloid cells derived from tumor-bearing mice inhibit primary T cell activation induced through CD3/CD28 costimulation. *J. Immunol.* 165, 779–785
- 86 Pong, K. *et al.* (2001) Attenuation of staurosporine-induced apoptosis, oxidative stress, and mitochondrial dysfunction by synthetic superoxide dismutase and catalase mimetics, in cultured cortical neurons. *Exp. Neurol.* 171, 84–97
- 87 Mollace, V. *et al.* (2002) The contribution of oxidative stress in apoptosis of human-cultured astroglial cells induced by supernatants of HIV-1-infected macrophages. *J. Leukoc. Biol.* 71, 65–72
- 88 Buccellato, L.J. *et al.* (2004) Reactive oxygen species are required for hyperoxia-induced Bax activation and cell death in alveolar epithelial cells. *J. Biol. Chem.* 279, 6753–6760
- 89 Matsuo, M. *et al.* (2003) Diesel exhaust particle-induced cell death of cultured normal human bronchial epithelial cells. *Biol. Pharm. Bull.* 26, 438–447
- 90 Pong, K. *et al.* (2002) Attenuation of zinc-induced intracellular dysfunction and neurotoxicity by a synthetic superoxide dismutase/catalase mimetic, in cultured cortical neurons. *Brain Res.* 950, 218–230
- 91 Pimentel, D.R. *et al.* (2001) Reactive oxygen species mediate amplitude-dependent hypertrophic and apoptotic responses to mechanical stretch in cardiac myocytes. *Circ. Res.* 89, 453–460
- 92 Kaul, S. *et al.* (2003) Caspase-3 dependent proteolytic activation of protein kinase C delta mediates and regulates 1-methyl-4-phenylpyridinium (MPP+)-induced apoptotic cell death in dopaminergic cells: relevance to oxidative stress in dopaminergic degeneration. *Eur. J. Neurosci.* 18, 1387–1401
- 93 Pong, K. *et al.* (2000) Prevention of 1-methyl-4-phenylpyridinium- and 6-hydroxydopamine-induced nitration of tyrosine hydroxylase and neurotoxicity by EUK-134, a superoxide dismutase and catalase mimetic, in cultured dopaminergic neurons. *Brain Res.* 881, 182–189
- 94 Trostchansky, A. *et al.* (2003) Peroxynitrite flux-mediated LDL oxidation is inhibited by manganese porphyrins in the presence of uric acid. *Free Radic. Biol. Med.* 35, 1293–1300
- 95 Frame, M.D. *et al.* (2002) Diminished arteriolar responses in nitrate tolerance involve ROS and angiotensin II. *Am. J. Physiol. Heart Circ. Physiol.* 282, H2377–H2385
- 96 Baboolal, H.A. *et al.* (2002) Reactive oxygen species scavengers attenuate endotoxin-induced impairment of hypoxic pulmonary vasoconstriction in mice. *Anesthesiology* 97, 1227–1233
- 97 Wang, C. *et al.* (2003) Blockage of phencyclidine-induced cortical apoptosis and deficits in prepulse inhibition by M40403, a superoxide dismutase mimetic. *J. Pharmacol. Exp. Ther.* 304, 266–271
- 98 Klein, M. *et al.* (2003) Meningitis-associated hearing loss: protection by adjunctive antioxidant therapy. *Ann. Neurol.* 54, 451–458
- 99 Cuzzocrea, S. *et al.* (2002) A role for superoxide in gentamicin-mediated nephropathy in rats. *Eur. J. Pharmacol.* 450, 67–76

## So – how are we doing?

***Drug Discovery Today* reviews all aspects of drug discovery – molecular targets, lead identification, lead optimization and associated technologies, drug delivery, gene therapy, vaccine development and clinical trials – together with overviews of the current status of compound classes and approaches in specific therapeutic areas or disease states.**

We welcome constructive comments about the content of *Drug Discovery Today* and encourage you to email the editorial team with your suggestions and comments.

Your comments and feedback are important in helping us shape this journal – we aim to provide information that you need.

Please send your comments to:

Dr Steve Carney

Editor

*Drug Discovery Today*

Drug Discovery Group, Elsevier, 84 Theobalds Road, London, UK WC1X 8RR

e-mail: [ddt@drugdiscoverytoday.com](mailto:ddt@drugdiscoverytoday.com)